Prevention and management of hyperphosphatemia with sevelamer in Canada: Health and economic consequences

Value in Health

Volumn 12, Issue 1, 2009, Pages 16-19

  Huybrechts, Krista F ^a,b   Caro, J Jaime ^a,b,c   O'Brien, Judith A ^a,b  

^a CARO RESEARCH INSTITUTE   (United States)

^b UNITED BIOSOURCE CORPORATION   (United States)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

Cardiovascular events; Cost effectiveness; Phosphate binders

Indexed keywords

PHOSPHATE; SEVELAMER;

ADULT; ARTICLE; CANADA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FEMALE; HEALTH CARE COST; HEART PROTECTION; HUMAN; HYPERPHOSPHATEMIA; MAJOR CLINICAL STUDY; MALE; MEDICARE; PRIORITY JOURNAL; UNITED STATES;

ADULT; AGED; CALCINOSIS; CALCIUM CARBONATE; CANADA; CARDIOVASCULAR DISEASES; CHELATING AGENTS; COST-BENEFIT ANALYSIS; HUMANS; HYPERPHOSPHATEMIA; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MODELS, ECONOMIC; POLYAMINES;

EID: 58849159266     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2008.00408.x     Document Type: Article

References (12)

1. London GM, Guerin AP, Marchais SJ, et al. Cardiac and arterial interactions in end-stage renal disease. Kidney Int 1996 50 : 600 8.
2. Pletcher MJ, Tice JA, Pignone M, Browner WS. Using the coronary artery calcium score to predict coronary heart disease events: a systematic review and meta-analysis. Arch Intern Med 2004 164 : 1285 92.
3. Block GA. Prevalence and clinical consequences of elevated Ca × P product in hemodialysis patients. Clin Nephrol 2000 54 : 318 24.
4. Chertow GM, Burke SK, Raggi P. Treat to Goal Working Group: sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002 62 : 245 52.
5. Huybrechts KF, Caro JJ, Wilson DA, O'Brien JA. Health and economic consequences of sevelamer use for hyperphosphatemia in patients on hemodiálisis. Value Health 2005 8 : 549 61.
6. Huybrechts KF, Caro JJ, London GM. Modeling the implications of changes in vascular calcification in patients on hemodialysis. Kidney Int 2005 67 : 1532 8.
7. Blacher J, Guérin AP, Pannier B, et al. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001 38 : 938 42.
8. Guérin AP, London GM, Marchais SJ, Metivier F. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 2000 15 : 1014 21.
9. Ontario Ministry of Health and Long-Term Care. Ontario Health Insurance (OHIP) Schedule of Benefits and Fees. Physician Services Schedule of Benefits, October 1, 2005.
10. Ontario Ministry of Health and Long-Term Care. Ontario drug benefit formulary/comparative drug index. Available from: https://www.healthinfo.moh. gov.on.ca/formulary/index.jsp [Accessed April 14, 2006].
11. Block GA, Raggi P, Bellasi A, et al. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007;71:438-41.
12. Collins AJ, St. Peter WL, Dalleska FW, et al. Hospitalization risks between Renagel phosphate binder treated and non-Renagel treated patients. Clin Nephrol 2000 54 : 334 41.